reports hero background
Updated: Nov 20, 2026
MPLT Logo

MapLight Therapeutics

NASDAQ:MPLT·Stock Analysis Report
Day Range
$6.11 - $6.48
Market Cap
360.85M
P/E Ratio
0.0000
Avg Value
$23.60
Year Range
$6.77 - $40.43
$6.27-$0.15 (-2.34%)
1
General Information
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders.

Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

2
MapLight Therapeutics (MPLT) Stock Graph
3
How We Grade MapLight Therapeutics (MPLT)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade MapLight Therapeutics (MPLT) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.

Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
5
Peer Ratings

See how MapLight Therapeutics compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
SPRYARS Pharmaceuticals
N/A
N/A
N/A
3.36
LRMRLarimar Therapeutics
N/A
N/A
N/A
24.22
AVTXAvalo Therapeutics
N/A
N/A
N/A
1.53
IRDOpus Genetics
N/A
N/A
N/A
95.41
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
6
Past Performance
How has MapLight Therapeutics (MPLT) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

MapLight Therapeutics (MPLT) sharpe ratio over the past 5 years is -0.4167 which is considered to be below average compared to the peer average of -0.1055


BenzingaBenzinga Japan